FEATURED ARTICLES

Breakthrough Therapy Designation Helps Genentech Navigate Difficult Trials Breakthrough Therapy Designation Helps Genentech Navigate Difficult Trials

FDA started the Breakthrough Therapy Designation program in 2012. Since then, Genentech has garnered 15 designations, more than any other company. Jeffrey Siegel has been an instrumental component of that success. Siegel is Genentech’s senior group medical director and spent 14 years with FDA prior to joining the company. He has spent most of his career in pharma developing products to address the unmet medical needs of patients. 

  • clinical news
    Clinical News Roundup: Is 80 Percent Of China's Clinical Data Fabricated?

    Radio Free Asia (RFA) is reporting that a government investigation in China has revealed fraudulent practice on a massive scale in clinical trials. China's food and drug regulator recently carried out a one-year review of clinical trials, concluding that more than 80 percent of clinical data is "fabricated," state media reported.

  • clinical news
    Clinical News Roundup: HHS To Provide More Info To Patients

    Clinical News Roundup for the week of September 19, 2016 with stories on HHS and ClinicalTrials.gov, FDA approval of Exondys51, DCRI coordinating National Study of Childhood Health, and the world's largest breath-based clinical trial.

  • SCDM Best Practices Now Available To Nonmembers
    SCDM Best Practices Now Available To Nonmembers

    Data managers are critical to the clinical research process. It’s the data they collect which will ultimately determine whether a new drug gains FDA approval. Recognizing that, the Society for Clinical Data Management (SCDM) was established to work with the teams creating clinical trials, writing the protocols, and identifying the information that needs to be captured. Over the years, the information gathered by SCDM members has been incorporated into a guide book of Good Clinical Data Management Practices, which SCDM is now making available to nonmembers as well as association members.

More Featured Articles

WHITE PAPERS & CASE STUDIES

  • What The Fitbit Is Helping Pharma Learn About Patients

    Fitness trackers were popular holiday gifts this year and sales are on the rise. While counting steps and getting fit may be the primary reason consumers are purchasing Fitbits and other wearables, other sensors these devices include, such as heart rate and sleep monitors, could actually help big pharma collect a wealth of valuable data to revolutionize personalized medicine.

  • Electronic Informed Consent: Considerations For Implementation In Clinical Trials

    In an era where data acquisition (eg. ePRO), capture (EDC) and storage (eTMF) are done electronically, it is the logical consequence to do the same for the informed consent process as all the advantages of the electronic modality equally apply to this process.

More White Papers & Case Studies

SERVICES & PRODUCTS

Data Standards

Decades of experience in CDISC standards implementation
We combine our decades of CDISC standards implementation expertise and regulatory experience to produce the highest quality clinical databases that allow regulatory reviewers to focus on your clinical results.

Marketing Applications

Setting the highest standards for marketing applications
A marketing application is the most critical milestone in your clinical research program. Quality applications can accelerate time to market, bring the benefit of new treatments to patients sooner, maximize research investments, and conserve patent life – demanding a partner with an insider’s understanding of the regulatory landscape and a proven track record for success.

Consulting

Clinical trials involve a myriad of complicated processes and variables. Rho can help you navigate the clinical trial process to save you time and minimize costs.

Clinical Data Management

Fast, flexible, and quality clinical data management
Clinical Data Management has undergone a rapid evolution, and the tools and processes of the last decade are not enough to ensure high-quality clinical data anymore. Grounded in a foundational knowledge of clinical data management best practices, our experts have developed system-agnostic, in-house data visualization and statistically-based anomaly detection and trend identification tools to provide actionable, risk-based insights and ensure the timely and accurate review of clinical trial data.

More Services & Products

NEWS

More News